(Q44388332)

2 December 2017

title

Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro (English)

1 reference

2 December 2017

1 reference

Trieb K

1

1 reference

2 December 2017

Blahovec H

series ordinal

2

1 reference

2 December 2017

publication date

1 July 2003

1 reference

International Journal of Biochemistry & Cell Biology

2 December 2017

published in

1 reference

2 December 2017

volume

35

1 reference

2 December 2017

issue

7

1 reference

2 December 2017

page(s)

1066-1070

1 reference

Redundancy of autocrine loops in human osteosarcoma cells.

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Tumor size and prognosis in aggressively treated osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Phosphate regulates the stability of skeletal alkaline phosphatase activity in human osteosarcoma (SaOS-2) cells without equivalent effects on the level of skeletal alkaline phosphatase immunoreactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Suramin affects differentiated and undifferentiated human thyroid epithelial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Reversible downregulation of telomerase activity by hyperthermia in osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Vascular smooth muscle cell proliferation is effectively suppressed by the non-specific growth factor inhibitor suramin

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Effect of suramin in a patient with adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study

1 reference

https://api.crossref.org/works/10.1016%2FS1357-2725%2802%2900308-4

7 January 2021

10.1016/S1357-2725(02)00308-4

Identifiers

DOI

1 reference

2 December 2017

1 reference